Search
Alabama Paid Clinical Trials
A listing of 1281 clinical trials in Alabama actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 1281
Alabama is currently home to 1281 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Major Depressive Disorder Clinical Study
Recruiting
Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorders
Featured Trial
Atopic Dermatitis (Eczema) Study
Recruiting
The purpose of this clinical study is to see whether an investigational injectable medication can help to treat symptoms of moderate to severe Atopic Dermatitis (eczema). You may qualify to participate if you were diagnosed with Atopic Dermatitis at least 1 year ago and are currently experiencing symptoms. Participants who qualify for the study will receive trial-related procedures and study medication at no cost. The site staff can provide you with additional details.
Conditions:
Atopic Dermatitis
Dermatitis
Atopic
Atopic Dermatitis Eczema
Atopic Eczema
* Compensation for time may be available
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
Recruiting
This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have cardiovascular or chronic kidney disease. People who have at least 2 health problems related to their weight or risks of cardiovascular disease can participate. Participants must have previously tried to lose weight by changing their diet.
The purpose of this study is to find out whether people with overweight or obesity who take a medicine called su... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: AMR Daphne, Daphne, Alabama
Conditions: Obesity
A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD
Recruiting
The purpose of this study is to demonstrate that the lung function effect from orally inhaled BGF delivered via HFO propellant is equivalent to the lung function effect from orally inhaled BGF delivered via HFA propellant in participants with COPD. The study duration for each participant will be approximately 15 to 16 weeks and consist of:
A screening and placebo run-in period of approximately 2 weeks prior to first dosing
Three treatment periods of approximately 4 weeks each (one period for ea... Read More
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
04/15/2024
Locations: Research Site, Sheffield, Alabama
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
Recruiting
This study is open to adults with a type of cancer called dedifferentiated liposarcoma (DDLPS). They can join the study if their tumours are positive for MDM2. The purpose of this study is to find out whether a medicine called brigimadlin (BI 907828) is tolerated by and helps people with DDLPS. Brigimadlin is a so-called MDM2 inhibitor that is being developed to treat cancer.
Participants take brigimadlin as a tablet once every 3 weeks. Participants may continue to take brigimadlin as long as t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Liposarcoma, Dedifferentiated
A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382
Recruiting
Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic disease requiring lifelong therapy. The purpose of this study is to assess change in disease activity, adverse events, tolerability, and how the drug moves through the body.
Budigalimab and ABBV-382 are investigational drugs being developed for the treatment of HIV disease. Participants are placed in 1 of 5 groups, called treatment arms. Each group r... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2024
Locations: University of Alabama at Birmingham, 1917 Research Clinic /ID# 257549, Birmingham, Alabama
Conditions: Human Immuno-deficiency Virus (HIV) Disease
Optimizing Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome (OPTimize NOW): A Symptom-Based Dosing Approach
Recruiting
This clinical trial will help us learn more about how to best care for babies with Neonatal Opioid Withdrawal Syndrome, also called NOWS. Babies with NOWS often have tremors, a hard time sleeping, excessive crying, and trouble feeding. Some babies that have NOWS need medicine. Doctors have two ways of providing medicine that are widely used today:
Scheduled opioid taper approach. The baby gets medicine at regular times. As symptoms get better, the amount of medicine the baby gets decreases unti... Read More
Gender:
All
Ages:
Between 1 hour and 48 hours
Trial Updated:
04/15/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Neonatal Opiate Withdrawal Syndrome
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
Recruiting
This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE).
The purpose of the core period (52 weeks of treatment) of this study is to evaluate the efficacy, safety, and tolerability of remibrutinib (LOU064) vs. placebo in adults suffering from CINDU inadequately controlled by H1-antihistamines (H1-AHs).
The purpose of the OLE period is to collect long-term efficacy, safety, and tolerability data o... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Allervie Clinical Research, Birmingham, Alabama
Conditions: Chronic Inducible Urticaria
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
Recruiting
The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The study will last approximately 54 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Syed Research Consultants Llc, Sheffield, Alabama
Conditions: Type 2 Diabetes
Study to Evaluate Efficacy When Transitioning From a Current Disease Modifying Therapy (DMT) to Ublituximab
Recruiting
The primary purpose of this phase 3b study is to assess efficacy after transition from a current DMT to ublituximab, as measured by T1 Gadolinium (Gd)-enhancing lesions.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/15/2024
Locations: TG Therapeutics Investigational Trial Site, Birmingham, Alabama
Conditions: Relapsing Multiple Sclerosis
Nutrition for Precision Health, Powered by the All of Us
Recruiting
The goal of this investigational study is to develop algorithms that predict human response to foods. The main question it aims to answer are:
How does varying foods and eating patterns impact one's biological and physiological responses?
In what ways can novel dietary assessment measures be used to improve dietary assessments and to prescribe assessments to people in future research with increased precision?
Can artificial intelligence and machine learning techniques be combined to prescribe f... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Nutrition, Health, Dietary Habits
A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Local Institution - 0082, Birmingham, Alabama
Conditions: Cardiomyopathy, Hypertrophic
A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms
Recruiting
This study is open to adults aged 18 and older or above legal age who have systemic sclerosis. People can participate if they have a specific subtype called diffuse cutaneous systemic sclerosis. People with another subtype called limited cutaneous systemic sclerosis can also participate if they are anti Scl-70 antibody positive. Systemic sclerosis is also called scleroderma.
The purpose of this study is to find out whether a medicine called Avenciguat (BI 685509) helps people with scleroderma w... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Scleroderma, Systemic
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
Recruiting
The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 studies.
This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Allervie Clinical Research, Birmingham, Alabama
Conditions: Chronic Spontaneous Urticaria